phrykt

Ensysce Biosciences, Inc. (ENSC): who owns it and who trades it

As of Nov 16, 2026, ENSC insiders reported 2 purchases worth $444K in the last 12 months. The largest buyer was Bob G Gower (Director), with $444K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ensysce Biosciences

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, ENSC insiders reported $444K of open-market purchases and $0 of sales.

Purchases, 12 months
$444K
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 7, 2026
Filed Aug 18, 2026

Purchases and sales by month

$244K$244KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 7, 2026Bob G GowerDirectorPurchase400,000$0.50$200KForm 4
Apr 23, 2026Bob G GowerDirectorPurchase508,614$0.48$244KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bob G GowerDirector$444K–Aug 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ENSC short interest

Low short interest. 0.5% of ENSC shares are sold short: about 1 share in 220. Over the last 12 reports the number of shares short went down 89%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 88,607 ENSC shares were sold short, 0.5% of the shares outstanding, down 70.8% from the report before. At the average daily volume of 264,785 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.46%May 15Oct 3010.0%

Days to cover

1.0May 15Oct 303.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202688,6070.46%-71%264,7851.0
Oct 15, 2026303,9561.56%-72%804,7371.0
Sep 30, 20261.08M5.56%-10%322,6643.4
Sep 15, 20261.21M6.20%-15%690,4531.8
Aug 31, 20261.43M7.33%+25%1.23M1.2
Aug 14, 20261.14M5.86%+496%84.96M1.0
Jul 31, 2026191,2912.06%-53%244,5821.0
Jul 15, 2026403,3344.35%+121%2.24M1.0
Jun 30, 2026182,3531.97%-50%1.05M1.0
Jun 15, 2026364,2783.93%+620%1.39M1.0
May 29, 202650,6010.55%-94%874,3101.0
May 15, 2026814,6058.78%+1445%8.67M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ensysce Biosciences company events

Ensysce Biosciences filed 17 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, listing). The latest was on Nov 4, 2026.

  1. Nov 4, 2026LeadershipEnsysce Biosciences Inc. has been advised by Mr. Will Chang, a member of the Company’s Board of Directors, that he intends to resign as a Director of the Company following the next annual meeting of stockholders. Filing
  2. Sep 29, 2026RulesChanged its bylaws or articles. Filing
  3. Aug 25, 2026AnnouncementAs previously reported, on May 21, 2026, Ensysce Biosciences Inc. received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule… Filing
  4. Aug 24, 2026AnnouncementAs previously reported, on August 5, 2026, the Company acquired Cy Biopharma, Inc., a Delaware corporation, and entered into a Securities Purchase Agreement with the purchasers thereto. Filing
  5. Aug 13, 2026ResultsReleased financial results. Filing
  6. Aug 6, 2026LeadershipResignation of Lynn Kirkpatrick as President and Appointment of James Morrison as President and Director Pursuant to the Merger Agreement, on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing. Filing
  7. Jul 15, 2026LeadershipEnsysce Biosciences Inc. received a resignation notice, dated and effective July 10, 2026, from Jeffrey Millard, who served as our Chief Operating Officer. Filing
  8. May 22, 2026ListingEnsysce Biosciences Inc. received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is… Filing
  9. May 15, 2026ResultsReleased financial results. Filing
  10. Apr 8, 2026AgreementAs previously reported in a Current Report on Form 8-K filed on November 17, 2025, on November 13, 2025, Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement directly with an institutional investor. Filing
  11. Apr 3, 2026LeadershipEnsysce Biosciences Inc. received a resignation notice, dated and effective April 1, 2026, from Curtis Rosebraugh, a member of our Board of Directors. Filing
  12. Mar 30, 2026ResultsReleased financial results. Filing
  13. Mar 30, 2026LeadershipEnsysce Biosciences Inc. received a resignation notice, dated and effective March 24, 2026, of Lee Rauch, a member of our Board of Directors. Filing
  14. Mar 23, 2026RulesChanged its bylaws or articles. Filing
  15. Feb 27, 2026ListingEnsysce Biosciences Inc. received a notice from the listing qualifications department staff of The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the… Filing
  16. Jan 8, 2026VoteReported shareholder vote results. Filing
  17. Nov 17, 2025AgreementEnsysce Biosciences, Inc. entered into a Securities Purchase Agreement directly with an institutional investor, pursuant to which the Company agreed to issue and sell in a registered direct offering, (i) 1,513 shares of Series B Preferred Stock of the Company, par value $0.0001 per share, as well… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ensysce Biosciences financials

Famous investors that hold ENSC

2 of the 50 well-known investors we track reported holding ENSC in their latest 13F filing. The largest position is Ken Griffin's, worth $101K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026243,089$101K0.0%+182%
Jim Simons · Renaissance TechnologiesQ3 202630,160$12.5K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Ensysce Biosciences, Inc. (ENSC) stock

Are ENSC insiders buying or selling?

In the last 12 months, ENSC insiders reported 2 open-market purchases worth $444K and no sales. The latest trade was on Aug 7, 2026. See every trade.

What is the short interest in ENSC?

As of Oct 30, 2026, 88,607 ENSC shares were sold short, 0.5% of the shares outstanding, down 70.8% from the report before. At the average daily volume of 264,785 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold ENSC?

2 of the 50 well-known investors we track reported ENSC in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $101K. See all holders.

Executive pay

Ensysce Biosciences's chief executive was paid a total of $487K for the year ended Dec 31, 2025, up 10% from $442K the year before. In the last 12 months, Ensysce Biosciences's executives and directors bought $444K of stock on the open market and sold none.

Chief executive, total pay$487KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$470KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$394KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.